insights_auto
688235 주가가 상승한 이유: 4.06%?
자세히 알아보기chevron_right
688235:SHA
베이진
CN¥255.98
arrow_upward
+4.06%(+9.99) 1D
10월 16일, 오후 3시 0분 0초 GMT+8 · CNY
search
모든 종목 코드
| 종목 코드 | 가격 | 변동 | 변동률(%) |
|---|
insights_auto688235의 주요 통계 생성 중...
시가
CN¥253.20
고가
CN¥268.18
저가
CN¥252.09
시가총액
2890.35억
평균 거래량
280.91만
거래량
568.77만
주가수익률
91.43
52주 최고가
CN¥319.24
52주 최저가
CN¥205.51
EPS
CN¥2.80
직원 수
1만
시가
CN¥253.20
고가
CN¥268.18
저가
CN¥252.09
시가총액
2890.35억
평균 거래량
280.91만
거래량
568.77만
주가수익률
91.43
52주 최고가
CN¥319.24
52주 최저가
CN¥205.51
EPS
CN¥2.80
직원 수
1만
뉴스 기사
웹 소스 및 뉴스 파트너 제공
프로필
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
베이진에 관한 정보